Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays

Andreas Hillarp | Karin Strandberg | Kerstin M. Gustafsson | Tomas L. Lindahl

Abstract

Introduction: Dilute Russell viper venom time (dRVVT) assays can be affected by direct oral anticoagulants (DOACs), which may cause false-positive results. However, there are conflicting results indicating significant differences between different reagents and DOACs.

Objectives: To evaluate the effect of DOACs on dRVVT assays.

Material and Methods: Samples were prepared by adding DOAC (dabigatran, rivaroxaban, apixaban, or edoxaban) to pooled normal plasma in the concentration range 0 to 800 µg/L. Six integrated dRVVT reagents were used, all composed of a screen assay (low phospholipid content) and a confirm assay (high phospholipid content). The screen/confirm dRVVT results were expressed as normalized ratios. To further evaluate the observed differences between tests and DOACs, addition of synthetic phospholipids was used.

Results: The dRVVT ratios increased dose dependently for all DOACs, with four of the six tests and the DOAC rivaroxaban having the greatest effect. With one test, the ratios were almost unaffected with increasing DOAC concentration, whereas another test revealed a negative dose dependency for all DOACs. Variable DOAC effects can be explained by different effects on dRVVT screen and confirm clotting time. Adding synthetic phospholipids to samples containing rivaroxaban resulted in greatly reduced screen clotting times and thereby lower calculated dRVVT ratios.

Conclusions: There is a great variability in the dRVVT test result with different DOACs. The dRVVT ratios are unaffected for some reagents and this can be explained by an equal dose-dependent effect on both screen and confirm assays. The phospholipid type and content of the different reagents may contribute to the observed differences.
INTRODUCTION

The direct oral anticoagulants (DOAC) represent a new class of drugs that are increasingly replacing vitamin K antagonists in indications such as the prevention of stroke in patients with atrial fibrillation and the treatment and secondary prevention of venous thromboembolism.\(^1\) During the past decade, four different DOACs have been introduced: the thrombin inhibitor dabigatran and three factor Xa inhibitors named rivaroxaban, apixaban, and edoxaban. It is well known that the DOACs may interfere with common coagulation assays,\(^5\)\(^-\)\(^8\) making it difficult to evaluate patient coagulation status during anticoagulant therapy. This interference also includes laboratory testing for lupus anticoagulant (LA) antibodies, a specific class of antiphospholipid antibodies that are prothrombotic in nature. LA testing is part of a laboratory panel for thrombophilia investigations because patients with LA have an increased risk for both arterial and venous thrombosis.\(^9\)\(^-\)\(^11\)

The most commonly used LA test is the dilute Russell viper venom time (dRVVT). The reagent contains a factor X activating (FXa) enzyme, the resultant FXa then forms the phospholipid-dependent prothrombinase assembly to generate thrombin, and the clotting time is registered.\(^12\) Because antibodies of the LA-type are dependent on phospholipids, it is possible to probe this activity by varying the phospholipid content; low phospholipid content LA prolongs the dRVVT more compared with a reagent with higher phospholipid content. Thus, the LA test is often performed as an integrated test based on two steps: one dRVVT screen test with low phospholipid content that is sensitive for LA and one dRVVT confirmation test with high phospholipid content that is not. In clinical practice, it is recommended that the confirmation step is done only if the screen test is prolonged. There is also often a mixing step included after a prolonged screen test in the test algorithm in which the patient sample is mixed with equal volume of normal plasma to increase the specificity for LA. If the sample contains true LA antibodies, the screen test clotting time would be prolonged and much longer than the confirmation test clotting time. The result is often expressed as a normalized dRVVT screen/confirm ratio (or LA ratio). The ratio is close to 1 if there are no LA antibodies and increases with LA antibodies present.

As the dRVVT test is dependent on both factor Xa and thrombin, the test may be influenced by all DOACs in a dose-dependent manner. Indeed, there are now several interesting reports on DOAC interferences on different LA tests that warrant a cautious interpretation of the results when DOACs are present.\(^13\)\(^-\)\(^34\) The reports mainly emphasize the risk of false-positive LA test results during DOAC therapy (although the effects vary with the type of DOAC and the type of dRVVT reagent), indicating that a local validation of the test system might be necessary to avoid diagnostic problems.

There are also reports of opposite effects with apixaban that may cause false-negative dRVVT results.\(^22\)\(^,\)\(^34\) There is evidence in the literature that rivaroxaban has the greatest effect, whereas apixaban has the least effect (or even the opposite effect) on the dRVVT ratio, explained by different effects on the underlying dRVVT screen and confirm tests. However, the causes of these differences have not been elucidated. In this study, we have in a more systematic way tried to explore the variable effects by a direct head-to-head comparison of all four DOACs with six different integrated dRVVT tests.

MATERIALS AND METHODS

2.1 Material

Dabigatran, rivaroxaban, and edoxaban were purchased from Selleckchem. Apixaban was from Adooq Bioscience. Dimethyl sulfoxide was from Merck. A stabilized phospholipid emulsion, with defined content, was a kind gift from Dr. Steffen Rosén, Rossix. The emulsion, denoted TGT, contained 0.5 mmol/L phospholipids based on a mixture of 28 mol% phosphatidylyserine, 30 mol% sphingomyelin, and 42 mol% phosphatidylcholine. Platelet poor (<10 × 10\(^9\)/L) pooled normal plasma (PNP) was obtained from our local blood bank by mixing citrated plasma from 20 different healthy blood donors. The plasma was aliquoted and stored in −80°C freezer until use. An LA positive control plasma was obtained from Precision BioLogic.

2.2 Preparation of plasma samples

Stock preparations of 0.1 mg/mL of each DOAC were made by dissolving the drug in 100% dimethyl sulfoxide. The concentrations of the stock preparations were calculated using the molecular weight of the drugs and the use of a Sartorius QT6100 analytical scale to precisely determine the amount of drug dissolved in each solution. The stock solutions were further diluted 1:125 with PNP to obtain a concentration of 800 µg/L of each DOAC and then further diluted with PNP to obtain seven concentrations between...
0 and 800 µg/L. The samples were stored at −80°C until they were transported on dry ice to the participating laboratories for analysis.

### 2.3 | dRVVT assays

Six different integrated dRVVT reagents were used: LA1/LA2 from Siemens Healthcare Diagnostics; LA Screen/Confirm from Technoclone; HemosIL dRVVT Screen/Confirm from Instrumentation Laboratory SpA; StaClot DRVV Screen/Confirm from Stago; dRVV Screen/Confirm from Sekisui Diagnostics; and Hemoctot LA-S and LA-C from Hyphen BioMed. The assay from Siemens was run on a Siemens instrument model BCS-XP, the assays from Instrumentation Laboratory, Sekisui and Hyphen were all run on the ACL Top instrument from Instrumentation Laboratory and the assays from Technoclone and Stago were run on a STAR MAX instrument from Stago. All tests were run according to the manufacturer’s recommendations regarding pipetting volumes and incubation times. The screen/confirm ratio results were expressed as normalized ratios based on PNP; a value >1.2 was considered being positive as recommended by the manufacturers. DOACs are commonly reported to elevate screening test results more than confirmatory tests results, meaning that not only can screening test be false positive, but also the interpretation for the presence of a LA can be false positive. In this study, we disregarded from current testing algorithms because we would like to systematically investigate the DOAC effects on the different reagents with all samples. Thus, the dRVVT screen and dRVVT confirmation tests were performed irrespective if the dRVVT screen test was prolonged or not.

### 2.4 | Tests with additional phospholipids

To explore the nature of the variable effect on the dRVVT screen and confirmation tests, samples with DOAC were analyzed after addition of increasing amounts of phospholipids. The DOACs with the most pronounced and the least pronounced effects were chosen, rivaroxaban and apixaban, respectively. Both DOACs were tested at a fixed concentration of 400 µg/L in PNP. Increasing amounts of TGT were added to these samples to obtain phospholipid concentrations between 0 and 100 µmol/L. The samples were analyzed with five of the six dRVVT reagents on the ACL Top instrument. The StaClot DRVV Screen/Confirm from Stago could not be included in this exercise because of unavailability through our local supplier during the time of experiments.

### 2.5 | Statistics

All samples were run in duplicate and results are presented as mean. Graphs were constructed using the Sigma Plot 10.0 (Systat Software Inc.). Normalized ratios (NR) for dRVVT screen/confirm coagulation times were calculated as follows:

\[
NR = \left( \frac{\text{clotting time patient screen/clotting time PNP screen}}{\text{clotting time patient confirm/clotting time PNP confirm}} \right)
\]

### 3 | RESULTS

Integrated dRVVT reagents were variably and dose-dependently affected by plasma samples spiked with DOACs. Rivaroxaban had the greatest effect in four of the six investigated dRVVT reagents (the assays from Stago, Siemens, Technoclone, and IL) and the normalized ratios were invariably positive (>1.2) at concentrations above 50 µg/L rivaroxaban (Figure 1). One reagent (Sekisui assay) displayed negative dose dependency with all four DOACs, whereas the reagent from Hyphen showed a weakly dose-dependent increase of the dRVVT ratio with dabigatran but all the Xa inhibitors gave unaffected or slightly negative ratios with increasing amount of anticoagulant drugs in the samples.

The variable effects, as well as common features, of the six different dRVVT reagents are further illustrated in Figure 2, where all test results are compared for each DOAC and reagent. The reagents from Technoclone and Siemens were the most DOAC sensitive assays, followed by the reagent from Stago, although the inter-DOAC effects vary to a great extent. The reagents from IL and Hyphen showed mixed results with both positive and negative effects on the dRVVT ratios depending on the type of DOAC. The reagent from Sekisui was negatively affected by all four DOACs and resulted in dose-dependent reduction of the normalized dRVVT ratios.

Because the dRVVT ratios are calculated from the underlying dRVVT screen and confirmation times, it follows that the screen test is more affected compared with the confirmation test, and vice versa, when the spiked DOAC samples display a positive or negative dose dependency, respectively (not shown). Thus, when the dRVVT ratio is influenced by the DOACs, it is likely that the effects are in some way dependent on the phospholipid content in the screen and confirmation tests. This hypothesis was tested by spiking phospholipid to the samples containing 400 µg/L rivaroxaban or apixaban before the testing, which resulted in a phospholipid concentration-dependent reduction of the ratios for the dRVVT reagents that were most DOAC sensitive (Figure 3). This was explained by a selective effect on the underlying dRVVT screen test, whereas the dRVVT confirm test was almost left unaffected by the addition of extra phospholipids. The three investigated assays that resulted in false-positive ratios because of addition of 400 µg/L rivaroxaban (Technoclone, Siemens, and HemosIL) displayed a greater effect of the phospholipid on the dRVVT screen test compared with the dRVVT confirmation test. With two assays (Hemoctot and Sekisui), the underlying screen and confirmation tests were less affected by the addition of phospholipid in the samples and the normalized ratios were similarly unaffected by the phospholipid. Similar patterns were obtained.
DISCUSSION

The potential problems with testing for LA in patients on DOAC therapy have been illustrated in many reports.13–34 The main issue is that DOACs may cause false-positive LA results, but the effects seem to be dependent on both the type of DOAC and the LA reagent, making it difficult to compare results from published studies. In this investigation, we have tried to systematically evaluate the effects of four DOACs on six different commercially available integrated dRVVT tests. Our results clearly illustrate the heterogeneity in the DOAC effects. The differences between the DOACs, when each assay is looked at independently, are illustrated in Figure 1. All four DOACs display a dose-dependent increase of the dRVVT NR in three of the six assays. These results are in accordance with previous reports on the risk of false-positive results under certain conditions. With one of the reagents (HemosIL), a dose-dependent increase of the NR was only shown for rivaroxaban (up to a concentration of 400 µg/L) but not for the other DOACs. For the remaining two assays (Hyphen and Sekisui) the effects were less pronounced or opposite. Thus, we can confirm that the Hemoclot assay that was recently developed by Hyphen as a dRVVT reagent indeed is less sensitive to interferences by rivaroxaban as well as the other DOACs. When we display the results of each individual DOAC, as shown in Figure 2, it becomes clear that the reagents are not the same. All four DOACs display positive or negative dose-dependent curves (higher and lower NR) depending on the type of reagent. The ratios are explained by the effects on the underlying dRVVT screen and dRVVT confirmation clotting times. The most extreme DOAC effect in this sense is caused by rivaroxaban with a much greater effect on the dRVVT screen test compared with the dRVVT confirmation test in four of the six reagents. The DOAC with the least positive effect on the
FIGURE 2  The variable effect on different LA reagents. Each graph (A-D) illustrates the calculated mean normalized LA ratios for the six different dRVVT tests plotted against the separate DOAC concentrations. Assays are defined as: ▲ Siemens; ● IL; ▶ Technoclone; ▼ Sekisui; ▲ Stago; ◆ Hyphen. Missing values indicate that the dRVVT ratios were not possible to calculate due to unmeasurable dRVVT screen or confirmation tests.

FIGURE 3  Impact of phospholipid emulsions on the dRVVT screen and dRVVT confirm tests. A plasma sample with 400 µg/L rivaroxaban was spiked with phospholipid at concentrations between 0 to 100 (µmol/L)/L and analyzed with different LA reagents. The graphs represent (A) in the dRVVT screen results, (B) the dRVVT confirmation results, and (C) the dRVVT normalized ratios. Assays are defined as: ▲ Siemens; ● IL; ▶ Technoclone; ▼ Sekisui; ▲ Stago; ◆ Hyphen.
HILLARP et AL.

This phenomenon could also be seen for the FXa inhibitors apixaban and edoxaban with the Hemoclot dRVVT reagent, whereas the NR for rivaroxaban was almost unaffected by increasing concentrations. On the other hand, the FIIa inhibitor dabigatran displayed a weak, but positive, dose-dependent effect also with the Hemoclot assay.

When all results from this direct comparison are taken together it is clear that the effects of DOACs are not the same. With several assays, the effects can be ranked with rivaroxaban having the greatest influence on the NR and the other DOACs to a lesser extent. However, there are also surprisingly large differences between different reagents as illustrated in Figure 2, a phenomenon without an obvious explanation. The dRVVT test is a rather straightforward assay principle, where a defined plasma volume is mixed with Russell viper venom and phospholipids, thus it can be anticipated that the variability among commercially available tests should be low. However, the different reagents are not equivalent concerning their sensitivities toward LA as well as interfering substances, such as DOACs, shown in this investigation. This is probably the result of variation in the reagent composition, including source and amount of venom and/or phospholipids. Because the content and composition of lipids in the reagents is not declared by the manufacturers, we studied the effects of adding defined phospholipid emulsions to the samples before testing. By this approach, we found that the apparent differences between DOACs are, at least in part, explained by the phospholipid content. With increasing proportion of phospholipids in the reaction mixture, it was possible to reduce the selective prolongation of the dRVVT screen clotting time, whereas the dRVVT confirmation test was almost unaffected (Figure 3), which thereby reduced the NR.

Our study has limitations that need to be discussed. One obvious limitation is the use of spiked plasma samples instead of plasma from patients on DOAC therapy. However, there are now many studies that have reported DOAC interference on LA tests (and other coagulation tests) using different approaches and the results based on both in vitro and ex vivo samples are consistent. Based on our study and the literature, we believe that our results are clinically applicable in the sense that it is possible to predict the relative DOAC sensitivities for the investigated dRVVT reagents. However, we cannot predict decision levels (ie, at what DOAC concentration we can anticipate a false [high or low] LA ratio in a given patient sample). For classification in tentatively positive results, we have used the manufacturer-recommended cutoff for normalized ratio. These recommended ratios are usually only valid for a certain analytical platform and in this investigation, we had to run three of the six reagents on other instruments for logistical reasons. Nevertheless, all manufacturers recommended that the cutoff, expressed as NR, is >1.2; this was therefore chosen as the cutoff in our study. Another limitation is that the experiments with synthetic phospholipids only aimed at explaining the risk of false high dRVVT ratios using rivaroxaban. Some reagents led to false low dRVVT ratios and, although the reason for this effect was not examined in our study, this may also be explained by the phospholipid content but needs to be further explored in new studies. We would also need to include true LA positive patient samples to investigate if DOACs interferences with these reagents could lead to false negative LA results.

Recent guidelines about LA testing recommend not testing for LA while patients are taking DOACs. To circumvent the problem of DOAC interference, alternative tests that are not affected by rivaroxaban (and possibly other DOACs), such as the Taipan venom time have been suggested. However, the clinical value of this assay in LA testing is less well documented compared with the dRVVT and is not widely available. In our opinion, a practical solution to avoiding interferences by DOACs is to adsorb the drug by active charcoal (ie, through use of DOAC-adsorbent additives in the sample) before testing. We cannot recommend abstaining from the anticoagulant treatment to reduce the drug level before testing, mainly because this will leave the patient without anticoagulant protection, but also because a low level of DOAC is not a guarantee for correct interpretation of the dRVVT assay. A problem for the laboratory and the interpretation of test results is quite often lack of clinical information, for example the presence or absence of DOAC treatment. One way forward is to retest all samples positive for lupus anticoagulant with the use of DOAC adsorbent to avoid false-positive results. However, it is unknown if this approach will reduce the risk of false-negative results, and such a procedure will also pose financial and logistical restraints. Increasing the phospholipid content to reduce the DOAC effect is not feasible because this would reduce the LA sensitivity of the test as well. We believe that this study may contribute to the development of new dRVVT reagents with an improved phospholipid formula that is less sensitive to the effects of DOACs.

ACKNOWLEDGMENTS
The expert technical assistance of the following biomedical scientists is gratefully acknowledged: Anna-Karin Ståhlberg (Halmstad) and Heidi Isacson (Malmö). The phospholipid emulsion used in our experiments was kindly donated by Steffen Rosen, Rossix, Mölndal, Sweden.

CONFLICT OF INTEREST
None of the authors have any disclosures.

AUTHOR CONTRIBUTIONS
All authors contributed to the design of the study, interpretation of data, revision of manuscript, and final approval of manuscript. Andreas Hillarp and Tomas L. Lindahl wrote the manuscript. Kerstin M. Gustafsson drew the figures and performed experiments.

ORCID
Tomas L. Lindahl https://orcid.org/0000-0003-0174-8152
REFERENCES

1. Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart. 2019;106:10-17.
2. Generalova D, Cunningham S, Leslie SJ, Rushworth GF, McIver L, Stewart D. A systematic review of clinicians’ views and experiences of direct-acting oral anticoagulants in the management of nonvalvular atrial fibrillation. Br J Clin Pharmacol. 2018;84:2692-2703.
3. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-335.
4. Thaler J, Pabinger I, Ay C. Anticoagulant treatment of deep vein thrombosis and pulmonary embolism: the present state of the art. Front Cardiovasc Med. 2015;2:30.
5. Gosselin RC, Adcock DM. The laboratory’s 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost. 2016;14:886-893.
6. Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16:209-219.
7. Ten Cate H, Henskens YMC, Lancé MD. Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. Vox Scl Health Risk Manag. 2017:13:457-467.
8. Favaloro EJ, Lippi G. Laboratory testing in the era of non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost. 2015;41:208-227.
9. Amiral J, Peyrafitte M, Dunois C, Vissac AM, Seghatchian J. Antiphospholipid syndrome: current opinion on mechanisms involved, laboratory characterization and diagnostic aspects. Transfus Apher Sci. 2017;56:612-625.
10. Linnemann B. Antiphospholipid syndrome – an update. Vasa. 2018;47:451-464.
11. Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103.
12. Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun. 2000;15:173-178.
13. Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost. 2011;105:385-386.
14. van Os GMA, de Laat B, Kamphuisen PW, Meijers JCM, de Groot PHG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost. 2011;9:1657-1659.
15. Halbmaier W-M, Weigel G, Quehenberger P, et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med. 2012;50:1601-1605.
16. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost. 2013;109:127-136.
17. Martinuzzo ME, Barrera LH, D’Adamo MA, Otaso JC, Gimenez MI, Oyhamburu J. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol. 2013;36:144-150.
18. Hillarp A, Gustafsson KM, Faxälv L, et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost. 2014;12:1545-1553.
19. Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology. 2015;47:355-364.
20. Arachchilage DRJ, Mackie JJ, Efthymiou M, Isenberg DA, Machin SJ, Cohen H. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost. 2015;13:1264-1273.
21. Kim YA, Gosselin R, Van Cott EM. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coaugulation assays. Int J Lab Med. 2015;37:e81-e84.
22. Bonar R, Favaloro EJ, Mohammed S, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology. 2016;48:60-71.
23. Douxfils J, Chatelain B, Chatelain C, Dogné JM, Mullier F. Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost. 2016;115:368-381.
24. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hemat. 2016;38:505-513.
25. Murer LM, Pirruccello SJ, Koepsell SA. Rivaroxaban therapy, false-positive anticoagulant screening results, and confirmatory assay results. Lab Med. 2016;47:275-278.
26. Ratzius F, Lang M, Belik S, et al. Lupus-anticoagulant testing at NOAC trough levels. Thromb Haemost. 2016;116:235-240.
27. Antovic A, Norberg E-M, Berndtsson M, et al. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. Thromb Haemost. 2017;117:1700-1704.
28. Depreter B, Devreese KM. Dilute Russell’s viper venom time reagents in lupus anticoagulant testing: a well-considered choice. Chem Lab Med. 2017;55:91-101.
29. Hoxha A, Banzato A, Ruffatti A, Pengo V. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun Rev. 2017;16:173-178.
30. Seheult JN, Meyer MP, Bontempo FA, Chibisov I. The effects of indirect- and direct-acting anticoagulants on lupus anticoagulant assays. Am J Clin Pathol. 2017;147:632-640.
31. Pouplard C, Vayne C, Berthomet C, Guery EA, Delahousse B, Gruel Y. The Taipan snake venom time can be used to detect lupus anticoagulant in patients treated by rivaroxaban. Int J Lab Hematol. 2017;39:e60-e63.
32. Flieder T, Weiser M, Eller T, et al. Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants. Thromb Res. 2018;165:101-106.
33. Hillarp A, Strandberg K, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Lindahl TL. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. Scand J Clin Lab Invest. 2018;78:575-583.
34. Favaloro EJ, Mohammed S, Curnow J, Pasalic L. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. Pathology. 2019;51:292-300.
35. Moore GW, Peyrafitte M, Dunois C, Amiral J. Newly developed dilute Russell’s viper venom reagents for lupus anticoagulant detection with improved specificity. Lupus. 2018;27:95-104.
36. Moore GW, Savidge GF. Heterogeneity of Russell’s viper venom affects the sensitivity of the dilute Russell’s viper venom time to lupus anticoagulants. Blood Coagul Fibrinolysis. 2004;15:279-282.
37. Clinical and Laboratory Standards Institute (CLSI). Laboratory testing for the lupus anticoagulant; approved guideline. CLSI document H60-A. Wayne, PA: CLSI; 2014.
38. Favresse J, Lardinois B, Sabor L, et al. Evaluation of the DOAC-Stop® procedure to overcome the effect of DOACs on several thrombophilia screening tests. TH Open. 2018;2:e202-e209.
39. Platton S, Hunt C. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban. Int J Lab Hematol. 2018;41:227-233.
40. Favaloro EJ, Gilmore G, Arunachalam S, Mohammed S, Baker R. Neutralising rivaroxaban induced interference in laboratory testing.
for lupus anticoagulant (LA): a comparative study using DOAC Stop and andexanet alfa. *Thromb Res.* 2019;180:10-19.

41. Slavik L, Jacova J, Friedecky D, et al. Evaluation of the DOAC-Stop procedure by LC-MS/MS assays for determining the residual activity of dabigatran, rivaroxaban, and apixaban. *Clin Appl Thromb Hemost.* 2019;25:107602961987255.

42. Ząbczyk M, Kopytek M, Natorska J, Undas A. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants. *Clin Chem Lab Med.* 2019;57(9):1374-1381.

**How to cite this article:** Hillarp A, Strandberg K, Gustafsson KM, Lindahl TL. Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays. *J Thromb Haemost.* 2020;18:1866–1873. [https://doi.org/10.1111/jth.14829](https://doi.org/10.1111/jth.14829)